Results 1 to 10 of about 464,004 (267)

Temporal Trends in Diagnostic Hemodynamics and Survival of Patients with Pulmonary Hypertension: A Single-Center Study

Life, 2023
Advances in the diagnosis and treatment of pulmonary hypertension (PH) have gradually improved the disease course. This retrospective cohort study aims to explore the diagnostic hemodynamic profile and survival of PH patients and their temporal changes ...
Georgios E. Papadopoulos, Alexandra Arvanitaki, Eleftherios Markidis, Sophia Anastasia Mouratoglou, Ioannis T. Farmakis, Panagiotis Gourgiotis, Thomas Chrysochoidis Trantas, Christos Feloukidis, Antonios Kouparanis, Matthaios Didagelos, Vasilis Grosomanidis, Antonios Ziakas, George Giannakoulas   +12 more
doaj   +1 more source

Chronic thromboembolic pulmonary hypertension following long-term peripherally inserted central venous catheter use

Pulmonary Circulation, 2019
A 36-year-old woman presented with recurrent pulmonary emboli (PE) despite oral anticoagulation. She was a type I diabetic with severe gastroparesis requiring insertion of multiple long-term peripherally inserted central catheters (PICC) over a 10-year ...
Abigail Masding, Stephen D. Preston, Mark Toshner, Joseph Barnett, Carl Harries, Konstantinos Dimopoulos, Aleksander Kempny, Colm McCabe, David P. Jenkins, S. John Wort, Laura C. Price   +10 more
doaj   +1 more source

Macitentan in daily clinical practice: A single centre, 1-year experience

Pulmonology, 2018
The effectiveness and safety of macitentan, a dual endothelin-receptor antagonist (ERA) approved for the treatment of pulmonary arterial hypertension (PAH), were shown in an extensive clinical trial oriented towards morbidity and mortality events.
S. Cadenas-Menéndez, P. Álvarez-Vega, J. Martín-Moreiras, M. Barreiro-Pérez, M.Á. Gómez-Sánchez, P.L. Sánchez-Fernández   +5 more
doaj   +3 more sources

Prospective clinical assessment of patients with pulmonary arterial hypertension switched from bosentan to macitentan (POTENT)

Pulmonary Circulation, 2022
Even though pulmonary arterial hypertension (PAH) remains an incurable disease, the combination of PAH‐specific therapies allowed treatment strategies to evolve from symptom‐based ones to others that aim to move patients to low‐risk conditions ...
Abdullah M. Aldalaan, Sarfraz A. Saleemi, Ihab Weheba, Abeer Abdelsayed, Maha M. Aleid, Fatima Alzubi, Hamdeia Zaytoun, Nadeen Alharbi   +7 more
doaj   +1 more source

Pulmonary hypertension associated with left-sided heart disease

Swiss Medical Weekly, 2017
Pulmonary hypertension associated with left-sided heart disease (PH-LHD) is the most common type of pulmonary hypertension. In patients with left-sided heart disease, the presence of pulmonary hypertension is typically a marker of more advanced disease,
Micha T. Maeder, Otto D. Schoch, Rebekka Kleiner, Lucas Joerg, Daniel Weilenmann, Swiss Medical Weekly   +5 more
doaj   +1 more source

The patient experience of pulmonary hypertension: a large cross-sectional study of UK patients

BMC Pulmonary Medicine, 2019
Background Pulmonary Hypertension Association UK (PHA-UK) is the only charity in the UK especially for people affected by pulmonary hypertension (PH).
Iain Armstrong, Catherine Billings, David G. Kiely, Janelle Yorke, Carl Harries, Shaun Clayton, Wendy Gin-Sing   +6 more
doaj   +1 more source

Hypochromic red cells as a prognostic indicator of survival among patients with systemic sclerosis screened for pulmonary hypertension

Arthritis Research & Therapy, 2023
Background Patients with systemic sclerosis (SSc) are frequently affected by iron deficiency, particularly those with pulmonary hypertension (PH). The first data indicate the prognostic importance of hypochromic red cells (% HRC) > 2% among patients with
Panagiota Xanthouli, Ojan Gordjani, Nicola Benjamin, Satenik Harutyunova, Benjamin Egenlauf, Alberto M. Marra, Simon Haas, Nicklas Milde, Norbert Blank, Hanns-Martin Lorenz, Christoph Fiehn, Silvia Ulrich, Oliver Distler, Ekkehard Grünig, Christina A. Eichstaedt   +14 more
doaj   +1 more source

Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study)

Arthritis Research & Therapy, 2019
Objective The objective of this randomized, placebo-controlled, double-blind, parallel group, trial was to assess the effect of ambrisentan on mean pulmonary arterial pressure (mPAP) in patients with systemic sclerosis (SSc) and mildly elevated pulmonary
Zixuan Pan, Alberto M. Marra, Nicola Benjamin, Christina A. Eichstaedt, Norbert Blank, Eduardo Bossone, Antonio Cittadini, Gerry Coghlan, Christopher P. Denton, Oliver Distler, Benjamin Egenlauf, Christine Fischer, Satenik Harutyunova, Panagiota Xanthouli, Hanns-Martin Lorenz, Ekkehard Grünig   +15 more
doaj   +1 more source

Pulmonary hypertension in chronic lung diseases: comparison to other pulmonary hypertension groups

Pulmonary Circulation, 2018
Group 3 pulmonary hypertension (PH) is a common complication of advanced chronic lung disease. Our hypothesis was that group 3 PH is associated with a more severe baseline presentation and a more severe prognosis compared to group 1 pulmonary arterial ...
Nader Chebib, Jean-François Mornex, Julie Traclet, François Philit, Chahera Khouatra, Sabrina Zeghmar, Ségolène Turquier, Vincent Cottin   +7 more
doaj   +1 more source

Long-term oxygen therapy in precapillary pulmonary hypertension – SOPHA study

Scientific Reports
Current guidelines recommend oxygen (O2) supplementation in patients with pulmonary hypertension (PH), despite scarce data on long-term O2 therapy (LTOT).
Nicola Benjamin, Ishan Echampati, Satenik Harutyunova, Christina Alessandra Eichstaedt, Benjamin Egenlauf, Silvia Ulrich, Ekkehard Grünig, Panagiota Xanthouli   +7 more
doaj   +1 more source